Consensus Corvus Pharmaceuticals, Inc.

Equities

CRVS

US2210151005

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-07 EDT			5-day change	1st Jan Change
1.68 ^USD	-12.04%		+8.39%	-4.55%

05-07	Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing	MT
05-07	Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating	MT

Evolution of the average Target Price on Corvus Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a3f3490f152a7e9c9d.0UpfOhnGxULW9lvN8vbZndoVms4jL9yG5W0Cx__hqpU.khJyY2qo8iaMhAyUwaGs06Bwz5RLHZb0lydV_reO3fSBew1Uf4qoD4C9Cg~1fcd1427eeaaf14236cfdc5cccc2068f

Analyst Recommendations on Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing	05-07	MT
Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $8 From $7, Maintains Outperform Rating	05-07	MT
Oppenheimer Trims Corvus Pharmaceuticals Price Target to $7 From $8, Maintains Outperform Rating	03-20	MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating	23-09-11	MT
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $8 From $7, Maintains Outperform Rating	23-09-07	MT
Oppenheimer Initiates Coverage on Corvus Pharmaceuticals With Outperform Rating, $7 Price Target	23-08-18	MT
Ladenburg Thalmann Adjusts Corvus Pharmaceuticals Price Target to $10 From $4, Maintains Buy Rating	23-05-30	MT
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $4 From $2, Maintains Overweight Rating	23-05-09	MT
Ladenburg Thalmann Starts Corvus Pharmaceuticals at Buy with $2 Price Target	22-10-07	MT
Cantor Fitzgerald Adjusts Corvus Pharmaceuticals' Price Target to $4 from $8, Keeps Overweight Rating	22-08-09	MT
Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $8 From $5, Maintains Overweight Rating	21-12-03	MT
Jefferies Reinstates Corvus Pharmaceuticals at Buy With $8 Price Target	21-12-01	MT
CORVUS PHARMACEUTICALS : Cantor Fitzgerald Adjusts Price Target on Corvus Pharmaceuticals to $5 From $10, Maintains Overweight Rating	21-08-03	MT
CORVUS PHARMACEUTICALS : Mizuho Securities Adjusts Corvus Pharmaceuticals' Price Target to $3.50 From $4, Maintains Neutral Rating	21-08-03	MT
CORVUS PHARMACEUTICALS : HC Wainwright Adjusts Corvus Pharmaceuticals' Price Target to $6 from $9.50, Keeps Buy Rating	21-07-16	MT
CORVUS PHARMACEUTICALS : Cantor Fitzgerald Starts Corvus Pharmaceuticals With Overweight Rating, $10 Price Target	21-05-27	MT
CORVUS PHARMACEUTICALS : HC Wainwright Adjusts Price Target on Corvus Pharmaceuticals to $9.50 From $12, Maintains Buy Rating	21-03-26	MT
CORVUS PHARMACEUTICALS : Mizuho Downgrades Corvus Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $4 From $7	21-02-10	MT
CORVUS PHARMACEUTICALS : Wedbush Adjusts Price Target on Corvus Pharmaceuticals to $6 From $8, Keeps Outperform Rating	20-11-02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.68 USD

Average target price

7.833 USD

Spread / Average Target

+366.27%

High Price Target

12 USD

Spread / Highest target

+614.29%

Low Price Target

3.5 USD

Spread / Lowest Target

+108.33%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Corvus Pharmaceuticals, Inc.

Oppenheimer
Ladenburg Thalmann
Cantor Fitzgerald
Jefferies & Co.
Mizuho Securities
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar